Genetic profile guides search for the right blood pressure drug

Nov 26, 2010

We are swimming in a sea of options when it comes to treating high blood pressure; there are currently more than half a dozen different classes of drugs on the market for the condition. Yet there is little rationale for giving individuals one particular drug over another.

Now, using a combination of key genes, researchers have developed a genetic profile that can identify at least one quarter of patients that react positively to the blood pressure drug rostafuroxin.

The findings may help doctors avoid the trial-and-error process commonly associated with matching the right blood pressure drug to the right patient.

Additionally, the “personalized medicine” platform may help to identify patients genetically predisposed to develop complications from certain blood pressure drugs. When blood exerts too much pressure on the walls of blood vessels, it's called hypertension, or . In 90 to 95 percent of hypertension cases the cause is unknown; but there are a few factors known to worsen high blood pressure, including smoking, obesity, consuming high amounts of salt, and stress.

Here, Chiara Lanzani, along with Mara Ferrandi and colleagues found that two factors--variants of the Adducin family of and high levels of hormone ouabain--are related to high blood pressure. Specifically, both mechanisms abnormally activate the sodium pump, a protein deployed to control body sodium and blood pressure.

Yet the increase in blood pressure caused by excessive sodium pump activation can be inhibited by the drug rostafuroxin at very low doses, the authors found. Next, in a phase II clinical trial, the team treated hypertension patients with rostafuroxin, and found that patients carrying particular genetic profile (made up of certain combinations of gene variants) responded positively to the drug, but not to other antihypertensive drugs.

The results indicate that the created by the researchers was able to predict the effectiveness of rostafuroxin (but not that of any other antihypertensive drugs) in patients carrying key gene variants.

Since the mechanisms blocked by rostafuroxin also underlie high blood pressure-related organ damage, this drug may also reduce risk of heart attack or other cardiovascular problems in patients, beyond that typically expected from reduced blood pressure alone.

Explore further: Muscular dystrophy: Repair the muscles, not the genetic defect

More information:
-- "Adducin- and Ouabain-Related Gene Variants Predict the Antihypertensive Activity of Rostafuroxin. Part 1: Experimental Studies," by M. Ferrandi et al., Science Translational Medicine.

-- "Adducin- and Ouabain-Related Gene Variants Predict the Antihypertensive Activity of Rostafuroxin. Part 2: Clinical Studies," by C. Lanzani et al. Science Translational Medicine.

add to favorites email to friend print save as pdf

Related Stories

Genes and drugs team up to lower blood pressure

Sep 13, 2007

Patients with high blood pressure respond very differently to antihypertensive medication, making treatment selection tricky for physicians. But new research published in the online open access journal, BMC Medical Genetics, pinpoi ...

'Less is more' when it comes to treating high blood pressure

Mar 19, 2009

A newly published study found patients actually have more control of their high blood pressure (hypertension) when treated with less medication. The study led by Dr. Ross D. Feldman, a clinical scientist with the Robarts ...

Recommended for you

Cellular protein may be key to longevity

11 hours ago

Researchers have found that levels of a regulatory protein called ATF4, and the corresponding levels of the molecules whose expression it controls, are elevated in the livers of mice exposed to multiple interventions ...

Gut bacteria tire out T cells

14 hours ago

Leaky intestines may cripple bacteria-fighting immune cells in patients with a rare hereditary disease, according to a study by researchers in Lausanne, Switzerland. The study, published in The Journal of Experimental Me ...

T-bet tackles hepatitis

14 hours ago

A single protein may tip the balance between ridding the body of a dangerous virus and enduring life-long chronic infection, according to a report appearing in The Journal of Experimental Medicine.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

junkd
not rated yet Nov 29, 2010
Reliable supplier, rapid delivery, guarantee!
http://star-of-he..._id=5831